Sex and the basic scientist: Is it time to embrace Title IX?

Biology of Sex Differences

Volumn 4, Issue 1, 2013, Pages

  Sandberg, Kathryn ^a   Verbalis, Joseph G ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891551688     PISSN: None     EISSN: 20426410     Source Type: Journal    
DOI: 10.1186/2042-6410-4-13     Document Type: Note

References (23)

1. United States Government Accounting Office: Drug Safety: Most drugs withdrawn in recent years had greater health risks for women. 2001 [http://www.gao.gov/new.items/d01286r.pdf]
2. United States Food and Drug Administration: Public health advisory: Reports of valvular heart disease in patients receiving concomitant fenfluramine and phentermine. 1997 [http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm180072. htm]
3. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH: Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993, 270(21):2590-2597. (Pubitemid 23346699)
4. United States Food and Drug Administration: FDA Drug Safety Communication: Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). 2013 [http://www.fda.gov/Drugs/DrugSafety/ ucm334033.htm]
5. United States Government Accounting Office: Women's Health: FDA needs to ensure more study of gender differences in prescription drug testing. 1992 [http://archive.gao.gov/d35t11/147861.pdf]
6. United States Food and Drug Administration: Guidance for Industry: General considerations for the clinical evalulation of drugs in infants and children. 1997 [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm071687.pdf]
7. Chen ML, Lee SC, Ng MJ, Schuirmann DJ, Lesko LJ, Williams RL: Pharmacokinetic analysis of bioequivalence trials: implications for sexrelated issues in clinical pharmacology and biopharmaceutics. Clin Pharmacol Ther 2000, 68(5):510-521.
8. Pinnow E, Sharma P, Parekh A, Gevorkian N, Uhl K: Increasing participation of women in early phase clinical trials approved by the FDA. Womens Health Issues 2009, 19(2):89-93.
9. Yang Y, Carlin AS, Faustino PJ, Motta MI, Hamad ML, He R, Watanuki Y, Pinnow EE, Khan MA: Participation of women in clinical trials for new drugs approved by the food and drug administration in 2000-2002. J Womens Health (Larchmt) 2009, 18(3):303-310.
10. Kwekel JC, Desai VG, Moland CL, Vijay V, Fuscoe JC: Sex differences in kidney gene expression during the life cycle of F344 rats. Biol Sex Differ 2013: in press.
11. Yang X, Schadt EE, Wang S, Wang H, Arnold AP, Ingram-Drake L, Drake TA, Lusis AJ: Tissue-specific expression and regulation of sexually dimorphic genes in mice. Genome Res 2006, 16(8):995-1004. (Pubitemid 44162259)
12. van Nas A, Guhathakurta D, Wang SS, Yehya N, Horvath S, Zhang B, Ingram-Drake L, Chaudhuri G, Schadt EE, Drake TA, et al: Elucidating the role of gonadal hormones in sexually dimorphic gene coexpression networks. Endocrinology 2009, 150(3):1235-1249.
13. United States Food and Drug Administration: Guidance for Industry: E16 biomarkers related to drug or biotechnology product development: context, structure, and format of qualification submissions. 2011 [http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM267449.pdf]
14. Ozer JS, Dieterle F, Troth S, Perentes E, Cordier A, Verdes P, Staedtler F, Mahl A, Grenet O, Roth DR, et al: A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat Biotechnol 2010, 28(5):486-494.
15. Soldin OP, Chung SH, Mattison DR: Sex differences in drug disposition. J Biomed Biotechnol 2011, 2011:1-14.
16. Beery AK, Zucker I: Sex bias in neuroscience and biomedical research. Neurosci Biobehav Rev 2011, 35(3):565-572.
17. Maselli A, Matarrese P, Straface E, Canu S, Franconi F, Malorni W: Cell sex: a new look at cell fate studies. FASEB J 2009, 23(4):978-984.
18. United States Department of Justice: Equal access to education: Forty years of Title IX. 2012 [http://www.justice.gov/crt/about/edu/documents/ titleixreport.pdf]
19. Sandberg K, Ji H: Sex differences in primary hypertension. Biol Sex Differ 2012, 3(7):1-21.
20. Dunn SE, Steinman L: The gender gap in multiple sclerosis: intersection of science and society. JAMA Neurol 2013, 70(5):634-635.
21. Parexel International Corporation: Parexel Biopharmaceutical R&D Statistical Sourcebook. Waltham; 2008.
22. MacLellan WR, Wang Y, Lusis AJ: Systems-based approaches to cardiovascular disease. Nat Rev Cardiol 2012, 9(3):172-184.
23. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL: How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010, 9(3):203-214.